The beginning of the new era of monoclonal antibodies biosimilars use in oncology:current international guidelines and the results of clinical trial of the first Russian rituximab biosimilar in patients with B-cell non-Hodgkin’s lymphoma
This article contains the detailed analysis of current approach to non-clinical and clinical development of monoclonal antibody biosimilars which is described in current guidelines of the European Medicines Agency (2012). Requirements of European regulatory authorities regarding evidence, which allo...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Habib O.N.
2014-06-01
|
| Series: | Современная онкология |
| Subjects: | |
| Online Access: | https://modernonco.orscience.ru/1815-1434/article/view/26947 |
| _version_ | 1818134286098759680 |
|---|---|
| author | K D Kaplanov A Yu Zaritskey S M Alekseev R A Ivanov E V Chernyaeva |
| author_facet | K D Kaplanov A Yu Zaritskey S M Alekseev R A Ivanov E V Chernyaeva |
| author_sort | K D Kaplanov |
| collection | DOAJ |
| description | This article contains the detailed analysis of current approach to non-clinical and clinical development of monoclonal antibody biosimilars which is described in current guidelines of the European Medicines Agency (2012). Requirements of European regulatory authorities regarding evidence, which allows to demonstrate absence or presence of significant differences between biosimilar and original medicinal product are also discussed. There is the first publication of data from international clinical study of the 1st Russian rituximab biosimilar in patients with B-cell non-Hodgkin's lymphoma, which showed no differences with the reference medicinal product MabThera® in terms of efficacy and safety. |
| first_indexed | 2024-12-11T09:06:12Z |
| format | Article |
| id | doaj.art-0f759e734ec246f9b97f065efee445d1 |
| institution | Directory Open Access Journal |
| issn | 1815-1434 1815-1442 |
| language | Russian |
| last_indexed | 2024-12-11T09:06:12Z |
| publishDate | 2014-06-01 |
| publisher | IP Habib O.N. |
| record_format | Article |
| series | Современная онкология |
| spelling | doaj.art-0f759e734ec246f9b97f065efee445d12022-12-22T01:13:38ZrusIP Habib O.N.Современная онкология1815-14341815-14422014-06-01162384424167The beginning of the new era of monoclonal antibodies biosimilars use in oncology:current international guidelines and the results of clinical trial of the first Russian rituximab biosimilar in patients with B-cell non-Hodgkin’s lymphomaK D KaplanovA Yu ZaritskeyS M AlekseevR A IvanovE V ChernyaevaThis article contains the detailed analysis of current approach to non-clinical and clinical development of monoclonal antibody biosimilars which is described in current guidelines of the European Medicines Agency (2012). Requirements of European regulatory authorities regarding evidence, which allows to demonstrate absence or presence of significant differences between biosimilar and original medicinal product are also discussed. There is the first publication of data from international clinical study of the 1st Russian rituximab biosimilar in patients with B-cell non-Hodgkin's lymphoma, which showed no differences with the reference medicinal product MabThera® in terms of efficacy and safety.https://modernonco.orscience.ru/1815-1434/article/view/26947cd20biosimilarsmonoclonal antibodiesrituximabb-cell non-hodgkin’s lymphomacd20 |
| spellingShingle | K D Kaplanov A Yu Zaritskey S M Alekseev R A Ivanov E V Chernyaeva The beginning of the new era of monoclonal antibodies biosimilars use in oncology:current international guidelines and the results of clinical trial of the first Russian rituximab biosimilar in patients with B-cell non-Hodgkin’s lymphoma Современная онкология cd20 biosimilars monoclonal antibodies rituximab b-cell non-hodgkin’s lymphoma cd20 |
| title | The beginning of the new era of monoclonal antibodies biosimilars use in oncology:current international guidelines and the results of clinical trial of the first Russian rituximab biosimilar in patients with B-cell non-Hodgkin’s lymphoma |
| title_full | The beginning of the new era of monoclonal antibodies biosimilars use in oncology:current international guidelines and the results of clinical trial of the first Russian rituximab biosimilar in patients with B-cell non-Hodgkin’s lymphoma |
| title_fullStr | The beginning of the new era of monoclonal antibodies biosimilars use in oncology:current international guidelines and the results of clinical trial of the first Russian rituximab biosimilar in patients with B-cell non-Hodgkin’s lymphoma |
| title_full_unstemmed | The beginning of the new era of monoclonal antibodies biosimilars use in oncology:current international guidelines and the results of clinical trial of the first Russian rituximab biosimilar in patients with B-cell non-Hodgkin’s lymphoma |
| title_short | The beginning of the new era of monoclonal antibodies biosimilars use in oncology:current international guidelines and the results of clinical trial of the first Russian rituximab biosimilar in patients with B-cell non-Hodgkin’s lymphoma |
| title_sort | beginning of the new era of monoclonal antibodies biosimilars use in oncology current international guidelines and the results of clinical trial of the first russian rituximab biosimilar in patients with b cell non hodgkin s lymphoma |
| topic | cd20 biosimilars monoclonal antibodies rituximab b-cell non-hodgkin’s lymphoma cd20 |
| url | https://modernonco.orscience.ru/1815-1434/article/view/26947 |
| work_keys_str_mv | AT kdkaplanov thebeginningoftheneweraofmonoclonalantibodiesbiosimilarsuseinoncologycurrentinternationalguidelinesandtheresultsofclinicaltrialofthefirstrussianrituximabbiosimilarinpatientswithbcellnonhodgkinslymphoma AT ayuzaritskey thebeginningoftheneweraofmonoclonalantibodiesbiosimilarsuseinoncologycurrentinternationalguidelinesandtheresultsofclinicaltrialofthefirstrussianrituximabbiosimilarinpatientswithbcellnonhodgkinslymphoma AT smalekseev thebeginningoftheneweraofmonoclonalantibodiesbiosimilarsuseinoncologycurrentinternationalguidelinesandtheresultsofclinicaltrialofthefirstrussianrituximabbiosimilarinpatientswithbcellnonhodgkinslymphoma AT raivanov thebeginningoftheneweraofmonoclonalantibodiesbiosimilarsuseinoncologycurrentinternationalguidelinesandtheresultsofclinicaltrialofthefirstrussianrituximabbiosimilarinpatientswithbcellnonhodgkinslymphoma AT evchernyaeva thebeginningoftheneweraofmonoclonalantibodiesbiosimilarsuseinoncologycurrentinternationalguidelinesandtheresultsofclinicaltrialofthefirstrussianrituximabbiosimilarinpatientswithbcellnonhodgkinslymphoma AT kdkaplanov beginningoftheneweraofmonoclonalantibodiesbiosimilarsuseinoncologycurrentinternationalguidelinesandtheresultsofclinicaltrialofthefirstrussianrituximabbiosimilarinpatientswithbcellnonhodgkinslymphoma AT ayuzaritskey beginningoftheneweraofmonoclonalantibodiesbiosimilarsuseinoncologycurrentinternationalguidelinesandtheresultsofclinicaltrialofthefirstrussianrituximabbiosimilarinpatientswithbcellnonhodgkinslymphoma AT smalekseev beginningoftheneweraofmonoclonalantibodiesbiosimilarsuseinoncologycurrentinternationalguidelinesandtheresultsofclinicaltrialofthefirstrussianrituximabbiosimilarinpatientswithbcellnonhodgkinslymphoma AT raivanov beginningoftheneweraofmonoclonalantibodiesbiosimilarsuseinoncologycurrentinternationalguidelinesandtheresultsofclinicaltrialofthefirstrussianrituximabbiosimilarinpatientswithbcellnonhodgkinslymphoma AT evchernyaeva beginningoftheneweraofmonoclonalantibodiesbiosimilarsuseinoncologycurrentinternationalguidelinesandtheresultsofclinicaltrialofthefirstrussianrituximabbiosimilarinpatientswithbcellnonhodgkinslymphoma |